First test of new drug for rare, debilitating disease
NCT ID NCT05661916
Summary
This study tested the safety of a new drug called ALN-TTRSC04 in healthy volunteers. The drug is designed to treat a rare disease where a harmful protein builds up in the body. Researchers gave single, increasing doses to 96 people to see how their bodies handled it and to check for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN-MEDIATED AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
London, SE1 1YR, United Kingdom
Conditions
Explore the condition pages connected to this study.